Fulgent Genetics Management

Management criteria checks 2/4

Fulgent Genetics' CEO is Ming Hsieh, appointed in May 2016, has a tenure of 8.17 years. total yearly compensation is $5.31M, comprised of 18.8% salary and 81.2% bonuses, including company stock and options. directly owns 29.15% of the company’s shares, worth MX$3.09B. The average tenure of the management team and the board of directors is 4.3 years and 3.4 years respectively.

Key information

Ming Hsieh

Chief executive officer

US$5.3m

Total compensation

CEO salary percentage	18.8%
CEO tenure	8.2yrs
CEO ownership	29.1%
Management average tenure	4.3yrs
Board average tenure	3.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ming Hsieh's remuneration changed compared to Fulgent Genetics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$5m	US$1m	-US$168m
Sep 30 2023	n/a	n/a	-US$64m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$5m	US$948k	US$143m
Sep 30 2022	n/a	n/a	US$272m
Jun 30 2022	n/a	n/a	US$392m
Mar 31 2022	n/a	n/a	US$461m
Dec 31 2021	US$6m	US$664k	US$507m
Sep 30 2021	n/a	n/a	US$569m
Jun 30 2021	n/a	n/a	US$493m
Mar 31 2021	n/a	n/a	US$417m
Dec 31 2020	US$248k	US$240k	US$214m
Sep 30 2020	n/a	n/a	US$48m
Jun 30 2020	n/a	n/a	US$3m
Mar 31 2020	n/a	n/a	-US$459k
Dec 31 2019	US$240k	US$240k	-US$411k
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$240k	US$240k	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$240k	US$240k	-US$3m

Compensation vs Market: Ming's total compensation ($USD5.31M) is above average for companies of similar size in the MX market ($USD604.47K).

Compensation vs Earnings: Ming's compensation has increased whilst the company is unprofitable.

CEO

Ming Hsieh (68 yo)

8.2yrs

Tenure

US$5,309,167

Compensation

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Ming Hsieh	Chairman & CEO	8.2yrs	US$5.31m	29.15% $ 3.1b
Jian Xie	COO & President	6.3yrs	US$1.79m	1.38% $ 146.2m
Paul Kim	Chief Financial Officer	8.5yrs	US$1.78m	0.38% $ 40.1m
Hanlin Gao	Chief Scientific Officer & Laboratory Director	7.8yrs	US$1.49m	2.83% $ 300.2m
Natalie Prescott	General Counsel & Chief Privacy Officer	2.2yrs	no data	no data
Doreen Ng	VP of Operations & Compliance and GM of Houston Office	3.8yrs	no data	no data
Jakub Sram	Vice President of Business Development & Sales	9.5yrs	no data	no data
Ellen Tsui	Vice President of Human Resources	2.2yrs	no data	no data
Brandon Perthuis	Chief Commercial Officer	4.3yrs	no data	no data
Lawrence Weiss	Chief Medical Officer	3.2yrs	no data	no data
Ray Yin	President & Chief Scientific Officer of Fulgent Pharma	1.7yrs	no data	no data

4.3yrs

Average Tenure

58yo

Average Age

Experienced Management: FLGT *'s management team is considered experienced (4.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Ming Hsieh	Chairman & CEO	8.2yrs	US$5.31m	29.15% $ 3.1b
Regina Groves	Independent Non-Employee Director	1.5yrs	US$625.60k	0.0040% $ 421.5k
Linda Marsh	Independent Director	4.9yrs	US$270.50k	0.062% $ 6.6m
Michael Nohaile	Independent Non-Employee Director	1.9yrs	US$268.50k	0.0080% $ 845.2k

3.4yrs

Average Tenure

67yo

Average Age

Experienced Board: FLGT *'s board of directors are considered experienced (3.4 years average tenure).

Fulgent Genetics Management

Management criteria checks 2/4

Key information

Recent management updates

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Chief Financial Officer recently sold Mex$5.8m worth of stock

Chief Financial Officer recently sold Mex$1.0m worth of stock

COO & President recently sold Mex$824k worth of stock

Less than half of directors are independent

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Recent updates

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023)

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022)

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Chief Financial Officer recently sold Mex$5.8m worth of stock

Chief Financial Officer recently sold Mex$1.0m worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

COO & President recently sold Mex$824k worth of stock

First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Less than half of directors are independent

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Less than half of directors are independent

COO & President recently sold Mex$457k worth of stock

Less than half of directors are independent

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

Chief Financial Officer recently sold Mex$552k worth of stock

COO & President recently sold Mex$599k worth of stock

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold Mex$1.9m worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Investor sentiment improved over the past week

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

COO & President recently sold Mex$719k worth of stock

COO & President recently sold Mex$719k worth of stock

Chief Financial Officer recently sold Mex$1.3m worth of stock

First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021)

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Chief Financial Officer recently sold Mex$530k worth of stock

Chief Financial Officer recently sold Mex$530k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold Mex$1.1m worth of stock

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold Mex$1.3m worth of stock

Chief Operating Officer recently sold Mex$2.4m worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020)

Chief Financial Officer recently sold Mex$1.1m worth of stock

Chief Operating Officer recently sold Mex$1.1m worth of stock

Chief Operating Officer recently sold Mex$2.3m worth of stock

Second quarter 2021 earnings released: EPS US$2.74 (vs US$0.15 in 2Q 2020)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired CSI Laboratories, Inc.

Investor sentiment improved over the past week